Business context and reporting period
The filing is a Form 10-Q for the three months ended March 31, 2019. The registrant identifies itself as Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biotechnology company developing microRNA-targeted therapies—not Viridian Therapeutics, Inc. Investors should verify the issuer identity before relying on this summary.
Miragen had three clinical-stage candidates: cobomarsen and remlarsen, developed independently, and MRG-110, developed with Servier. It had no approved products and generated no product-sale revenue.
Financial results and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Total revenue | $0.4 million | $4.8 million |
| Research and development expense | $8.8 million | $6.4 million |
| General and administrative expense | $3.4 million | $3.0 million |
| Net loss | $11.6 million; $0.38 per share | $4.7 million; $0.18 per share |
| Operating cash used | $11.8 million | $7.4 million |
At March 31, 2019, cash and cash equivalents were $18.2 million and short-term investments were $32.8 million, totaling approximately $51.0 million. Current assets were $54.2 million versus current liabilities of $6.9 million. Management expected available resources to fund normal operations and liquidity needs for at least 12 months, while stating that additional capital would be needed thereafter.
Debt included $10.0 million of principal under a Silicon Valley Bank loan, with a $10.4 million reported carrying amount including the accreted final payment fee and other adjustments. The loan bears interest at prime (5.50% at quarter-end); $3.3 million was classified as current. The company reported no material off-balance-sheet arrangements. No gross margin was presented; the filing reports no product sales.
Material changes versus the prior comparable period
- Revenue fell by $4.4 million, mainly because Q1 2018 included a $3.7 million Servier development milestone and Q1 2019 had lower reimbursable research and development activity.
- Research and development expense increased $2.4 million, principally from cobomarsen SOLAR trial and related manufacturing costs; lower technology-license fees partly offset the increase.
- Net loss widened by $7.0 million. Operating cash use increased $4.4 million.
- Q1 2018 financing included $37.9 million net proceeds from a public offering; Q1 2019 financing provided $0.2 million, primarily from ATM and employee stock-plan sales.
Outlook, commentary, risks and unusual items
Management expected research and development spending and operating losses to rise as clinical programs advanced, with quarterly results likely to fluctuate. There was no specific financial earnings or revenue guidance. The company said it would need substantial additional capital beyond the next 12 months; future funding could require equity or debt financing, partnerships, or changes to development plans. Equity issuance could dilute shareholders, and the SVB loan restricts certain actions.
- Clinical milestones: First patients entered the Phase 2 SOLAR cobomarsen trial in April 2019; primary-endpoint data were expected in the second half of 2020. Remlarsen Phase 2 enrollment was complete, with data expected in the second half of 2019. MRG-110 Phase 1 enrollment was complete, with data expected in 2019.
- Development and regulatory risks: Candidates remain investigational; clinical outcomes, safety, enrollment, manufacturing, regulatory approval and commercial viability are uncertain. The microRNA approach is novel and no microRNA-targeted therapy had been approved at the time of filing. Accelerated approval for cobomarsen was a possibility discussed with FDA, not an assurance.
- Partner and licensing exposure: Servier reimbursement, milestones and potential royalties depend on development and other conditions; remaining milestone consideration was constrained because achievement was uncertain. Licenses also carry potential milestones and royalties.
- Other items: Adoption of ASC 606 and the non-employee share-based compensation standard had no material financial-statement impact. The company reported no material legal proceedings, and management concluded disclosure controls were effective at a reasonable level of assurance.
Important facts for investors to verify
- Confirm whether the intended filing is Miragen Therapeutics’ Q1 2019 10-Q or a filing for Viridian Therapeutics; the registrant named in this document is Miragen.
- Track cash, investment balances and quarterly cash burn against the stated 12-month liquidity outlook and future financing needs.
- Check subsequent clinical results and timing for SOLAR, remlarsen and MRG-110 against the milestones anticipated in the filing.
- Review Servier’s cost-sharing and milestone conditions, and the SVB loan’s repayment schedule, covenants and collateral provisions.
- Assess potential dilution from the ATM and LLS stock purchase arrangements and the execution, safety and regulatory risks of the clinical pipeline.